Glucosamine
Glucosamine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target P2Y purinoceptor 14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acts38 boswelliagel | unapproved drug other | 2022-09-07 |
| acts38 boswelliagel (100ml) | unapproved drug other | 2022-10-22 |
| artridon | C200263 | 2024-10-29 |
| deguli | unapproved drug other | 2022-02-21 |
| floriva | unapproved drug other | 2024-02-02 |
| glucosamine cream extra strength | C200263 | 2024-12-30 |
| glucosamine sulfate, chondroitin sulfate, ibuprofen | Export only | 2025-06-30 |
| goodoh energycream | unapproved drug other | 2023-11-30 |
| implaheal p.ocream | unapproved drug other | 2020-01-04 |
| jba joint revive | unapproved drug other | 2025-03-31 |
Show 10 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
141 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 3 | 2 | 12 | 11 | 27 | 54 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 3 | 2 | 7 | 8 | 22 | 41 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 2 | 3 | — | 5 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 2 | 1 | 1 | 5 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 3 | 2 | — | 5 |
| Syndrome | D013577 | — | — | — | 1 | 3 | 1 | — | 4 |
| Back pain | D001416 | — | M54 | — | — | — | 2 | 2 | 4 |
| Low back pain | D017116 | — | M54.5 | — | — | — | 1 | 2 | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | 2 | 3 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | 2 | — | 2 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 2 | 2 | — | — | 4 |
| Muscular diseases | D009135 | EFO_0002970 | G72.9 | — | 2 | 2 | — | — | 4 |
| Distal myopathies | D049310 | — | G71.09 | — | 2 | 2 | — | — | 4 |
| Inclusion body myositis | D018979 | EFO_0007323 | G72.41 | — | 1 | 2 | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | 1 | — | — | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | — | — | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | — | 1 | 2 |
| Recurrence | D012008 | — | — | 1 | — | 1 | — | — | 2 |
| Pulpitis | D011671 | EFO_1001139 | K04.0 | — | — | 1 | — | 1 | 2 |
| Ulcer | D014456 | MPATH_579 | — | 1 | — | 1 | — | — | 2 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | D018771 | — | M25.5 | — | 2 | — | — | 3 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | 1 | 4 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Respiratory tract neoplasms | D012142 | EFO_0003853 | D14 | — | 1 | — | — | — | 1 |
| Bronchogenic carcinoma | D002283 | — | — | — | 1 | — | — | — | 1 |
| Thoracic neoplasms | D013899 | — | — | — | 1 | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | — | — | 1 |
| Severe acute malnutrition | D000067011 | — | — | — | 1 | — | — | — | 1 |
| Tinnitus | D014012 | — | H93.1 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 1 | 2 |
| Venous insufficiency | D014689 | — | — | 1 | — | — | — | 1 | 2 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 3 | 3 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | — | — | — | 2 | 2 |
| Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 2 | 2 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 2 | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
| Myalgia | D063806 | — | M79.1 | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | — | 1 | 1 |
Show 36 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Glucosamine |
| INN | glucosamine |
| Description | 2-amino-2-deoxy-D-glucopyranose is a D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2. It has a role as an Escherichia coli metabolite, a mouse metabolite and a geroprotector. It is functionally related to a D-glucopyranose. It is a conjugate base of a 2-ammonio-2-deoxy-D-glucopyranose. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 3416-24-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL493287 |
| ChEBI ID | 47977 |
| PubChem CID | 439213 |
| DrugBank | DB01296 |
| UNII ID | N08U5BOQ1K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
P2RY14
P2RY14
Organism
Homo sapiens
Gene name
P2RY14
Gene synonyms
GPR105, KIAA0001
NCBI Gene ID
Protein name
P2Y purinoceptor 14
Protein synonyms
G protein coupled receptor for UDP-glucose, G-protein coupled receptor 105, P2Y(14) receptor, P2Y14 receptor, purinergic receptor P2Y, G-protein coupled, 14, UDP-glucose receptor
Uniprot ID
Mouse ortholog
P2ry14 (140795)
P2Y purinoceptor 14 (Q9ESG6)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Glucosamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55,779 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,743 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use